70 results about "Treatment dose" patented technology

Techniques for adjusting radiotherapy treatment for a patient in real-time are provided. The techniques include obtaining a training patient anatomy at a first time within a training radiotherapy treatment fraction after a training radiotherapy treatment dose has been delivered by a radiotherapy device; computing a deviation between the training patient anatomy at the first time and reference training patient anatomy during the training radiotherapy treatment fraction, wherein the reference training patient anatomy indicates a prescribed training dose parameter to be delivered within the training radiotherapy treatment fraction; applying the computed deviation to a machine learning model to estimate one or more intra-fraction radiotherapy treatment parameters of a function that provides a radiotherapy device parameter adjustment based on the one or more intra-fraction radiotherapy treatment parameters; and training the machine learning model to establish a relationship between the computed deviation and the one or more intra-fraction radiotherapy treatment parameters.

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

The present application relates to the field of intelligent medical treatment, in particular to a tumor treatment dosing regimen Pareto optimization method based on forward-backward stochastic differential equation. The present application unifies the terminal tumor load, dosing cost and treatment risk into the same stochastic control framework, can establish the Pareto optimality condition corresponding to the nonlinear model, and further converts into the implementable closed-loop state feedback control law in the LQ case. Through the combination with the numerical example and the Pareto frontier analysis, an implementable, interpretable and scalable technical path is provided for the multi-objective individualized treatment regimen design, which can solve the problem that the existing technology is difficult to uniformly process the terminal therapeutic effect, dosing consumption and cumulative risk, and difficult to obtain the implementable closed-loop feedback strategy under the forward-backward stochastic control framework.

The invention provides a BNCT treatment dose accelerated calculation method, a terminal and a treatment planning system. The method comprises the steps of equally dividing each voxel block into a first voxel block and a second voxel block based on a three-dimensional coordinate of each voxel block in a voxel model; alternately iteratively executing the parallel computing process of the first voxel block and the parallel computing process of the second voxel block on the basis of a pre-constructed computing dependency relationship, and obtaining the neutron ejection flow and the neutron flux of each voxel block until an iteration stop condition is met; wherein the dependency calculation relation includes that parallel calculation of the first voxel block depends on neutron outgoing flow of the second voxel block, and parallel calculation of the second voxel block depends on neutron outgoing flow of the first voxel block; and calculating the BNCT therapeutic dose based on the neutron flux of each voxel block. According to the method, on the premise of strictly guaranteeing the calculation precision, a large-scale parallel calculation task set can be formed, the iteration convergence period and the overall calculation time consumption are reduced to the maximum extent, and the requirement for clinically and rapidly calculating the BNCT treatment dose is met.

The present invention concerns dosimetry-related uses and methods that rely on a metastable technetium-99 (99mTc) radionuclide-comprising (dosimetric) radioimmunoconjugate (RIC) to evaluate or establish therapeutic doses of yttrium-90 (90Y) radionuclide-comprising (therapeutic) radioimmunoconjugates, both RICs targeting the same molecular target. More specifically, radioimmunoconjugates that comprise a CD66-binding component are used. Another aspect of the invention relates to Single Time Point dosimetry procedures replacing the need for traditionally used Multiple Time Point dosimetry procedures for yttrium-90 (90Y) radionuclide-comprising radioimmunoconjugates.

The present invention provides a device, system, and method of using the same that can safely and effectively transmit therapeutic or germicidal ultraviolet (UV) radiation, such as UVC radiation or UVA radiation. [Solution] The treatment device comprises a base component and a head component. The head component has a distal portion and a proximal portion. The distal portion of the head component is configured to contact the target eyelid, and the proximal portion is configured to be attached to the base component. The distal portion of the head component is configured to transmit a therapeutic dose of energy from a plurality of energy sources, including an ultraviolet C (UVC) radiation source, an infrared (IR) radiation source, and an ultrasonic source. The plurality of energy sources are configured to transmit a therapeutic dose of energy to the target eyelid at a predetermined output when the distal portion of the head component contacts the eyelid.

The invention discloses an image segmentation method for evaluating a non-small cell lung cancer neutron treatment dose, and relates to the technical field of neutron therapy, and the method comprises the steps: carrying out the training of a 3D U-Net network model through a medical image data set, updating the network parameters and hyper-parameters in the 3D U-Net network model, so as to obtain a trained 3DU-Net network model, and carrying out the evaluation of the neutron treatment dose of the non-small cell lung cancer. In the aspect of processing three-dimensional volume data in an image, information of a space direction can be better reserved, segmentation of a three-dimensional structure can be more accurately carried out, and the segmentation form can accurately reflect an anatomical structure of a patient, a distribution condition of 10B in a body and a radionuclide dynamics condition. Therefore, the information in the medical image can be accurately and fully displayed, and application is facilitated.

The invention belongs to the technical field of biological medicine, and particularly relates to a heparin small molecule antagonist-quaternary ammonium salt macrocyclic compound and a preparation method thereof. The quaternary ammonium salt macrocyclic compound disclosed by the invention comprises three piperazine functionalized quaternary ammonium salt macrorings and four methylated quaternary ammonium salt macrorings; the quaternary ammonium salt macrocyclic compound can be used for preparing a heparin small molecule antagonist. The compound shows excellent antagonism efficiency on ungraded heparin and low-molecular-weight heparin, and shows a wide therapeutic dose window; and the antagonism efficiency and dosage window of the protamine are superior to those of clinically used protamine. Besides, in-vivo and in-vitro safety evaluation proves that the quaternary ammonium salt macrocycle has good biocompatibility, and shows clinical transformation potential as a protamine substitute as a small molecule antagonist.

The instant application describes improved methods and compositions for the systemic delivery of therapeutic exosomes to a subject in need thereof. In certain embodiments, the current invention reduces the amount of exosomes delivered to liver, spleen and combinations thereof to allow greater distribution to other areas of the body such as, but not limited to, the brain, pancreas, lung, kidney, muscle. In certain embodiments, the methods involve the injection of one or multiple doses of non-therapeutic exosomes prior to the injection of a suitable therapeutic dose of exosomes with a therapeutic payload. Also included are methods to improve immune clearance of exosomes in subjects by inhibiting phagocytosis.

It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by malignant pediatric tumor cells. The alkylphosphocholine analogs are compounds having the formula:or salts thereof, wherein n is an integer from 12 to 24; and R2 is —N+(CH3)3. The compounds can be used to treat pediatric solid tumors or to detect pediatric solid tumors. In therapeutic treatment, R1 includes a radioactive iodine isotope that locally delivers therapeutic dosages of radiation to the malignant pediatric tumor cells that preferentially take up the compound. In detection / imaging applications, R1 includes a detection moiety, such as a fluorophore or a radioactive iodine isotope.

The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid to administer to a patient in need thereof, comprising the steps of:(i) testing whether or not the patient has the poor metabolizer genotype; and(ii) if the patient does not have the poor metaboliser genotype, administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the standard therapeutic dose; and(iii) if the patient does have the poor metaboliser genotype, either(a) administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose below that of the standard therapeutic dose; or(b) not administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient.

A method is provided to modulated vascular adaptation within a tumor so that therapy uptake is increased. The method includes providing a pressure directed therapy system having an infusion lumen, an occluder, a pressure sensor to sense pressure distal of the occluder. The distal end of the system is advanced to a target artery of an organ. The pressure in the target artery is reduced by expanding the occluder at the distal end of the system. Then, the therapy is infused through the infusion lumen and into the target artery. Upon sensing decreased pressure and thus vessel adaptation, infusion is stopped until vessel re-adaptation occurs. Then infusion resumes. The infusion continues in a cycle of therapy infusing, sensing pressure and determining vessel adaptation, waiting, and resuming once re-adaptation occurs until the therapy dose is delivered to the patient.

Systems and methods are disclosed for treating back pain associated with a vertebral body of a patient. The system may include an external energy source configured to be positioned at a location external to the body of the patient, a linear configured to drive translation of the external source in one or more axes, a computer coupled to the external source and linear drive and programming executable on said computer for determining a target treatment site within or near the vertebral body based on acquired imaging data, positioning a focal point of the external energy source to substantially coincide with the target treatment site, and delivering a treatment dose of therapeutic energy at said target treatment site, wherein the treatment dose is configured to modulate a nerve within or near the vertebral body.

The invention relates to the technical field of intelligent medical control and low-temperature plasma medical application, in particular to an intelligent decision-making system for CAP treatment of nephropathy skin complications based on multi-parameter dynamic monitoring. Comprising a multi-modal physical sign acquisition module which is used for acquiring multi-dimensional physiological characterization signals of local tissues and synchronously acquiring periodic metabolism interference data containing dialysis time sequence information; the tolerance threshold inversion module is used for obtaining a local tissue oxidation-reduction tolerance threshold through inversion by using a tissue oxidation-reduction tolerance calculation model; the dynamic interference compensation module is used for generating a real-time safety boundary threshold value; the adaptive strategy generation module is used for generating candidate treatment control strategies by using a deep reinforcement learning algorithm; the risk boundary control module is used for calculating an expected oxidative stress level, if the expected oxidative stress level is larger than or equal to a real-time safety boundary threshold value, blocking or degrading operation is executed, and otherwise, a final treatment instruction is output; the therapeutic dose control precision is improved to the physiological response level, and the iatrogenic skin necrosis risk is effectively avoided.

The application discloses application of a compound SCH23390 in preparation of a medicine for treating lead poisoning, and relates to the technical field of medicines. The application studies the efficiency of the compound SCH23390 in treatment of lead poisoning, first discloses the treatment effect of the compound SCH23390 on lead poisoning, breaks through the limitation of an existing drug target point, directly corrects abnormal nerve signals by inhibiting excessive activation of D1 neurons, avoids side effects of central excessive excitation, and has no significant toxic side effects under a treatment dose. In particular, the compound SCH23390 can significantly relieve specific abnormal behavior phenotypes caused by low-dose lead poisoning, and exhibits better neuroprotective characteristics than traditional chelating agents. The application breaks through the limitation of a single chelating antidote in the traditional field of lead poisoning treatment, and provides a new direction for development of anti-lead toxicity medicines with multiple target points and multiple mechanisms.

Methods are provided for treating a subject with cancer, with a therapeutic dose of annexin V to the subject.

The utility model relates to the technical field of ultrasonic treatment equipment, in particular to an automatic treatment device with image guidance, which is characterized in that a host is arranged on one side of a control console, a follow-up arm is mounted on the control console, a first mounting hole is formed in the working end of the follow-up arm, a colposcope is mounted in the first mounting hole, a treatment arm is mounted at the working end of the follow-up arm, and the treatment arm is mounted on the control console. A second mounting hole and a third mounting hole are formed in the treatment arm, a treatment gun is mounted in the second mounting hole, a laser head is mounted in the third mounting hole, and the laser head, the treatment gun and the colposcope are all connected with the console. A colposcope image corresponds to coordinate information positioned by a laser head, so that accurate positioning and uniform movement of a treatment position are realized, non-uniform speed and inaccurate position of a treatment gun which is manually moved are avoided, and the treatment efficiency is improved; visualization of a real-time path and an ultrasonic dose when the treatment gun works is achieved, the condition of the treatment process is known in real time, the ultrasonic treatment dose is accurately mastered, the treatment position is accurately positioned, and the treatment mode is optimized.

A method and compositions of matter for treating or preventing an auto-immune disorder or immune response in a patient, that includes providing a therapeutic dose to the patient of a substituted indole compound having at least one substitution, wherein the substituted indole compound has only one thiol group, and wherein the ring the thiol group is attached to only contains one N or O atom.

Systems and methods are disclosed for treating back pain associated with a vertebral body of a patient. The system may include an external energy source configured to be positioned at a location external to the body of the patient, a linear configured to drive translation of the external source in one or more axes, a computer coupled to the external source and linear drive and programming executable on said computer for determining a target treatment site within or near the vertebral body based on acquired imaging data, positioning a focal point of the external energy source to substantially coincide with the target treatment site, and delivering a treatment dose of therapeutic energy at said target treatment site, wherein the treatment dose is configured to modulate a nerve within or near the vertebral body.

To provide a method for ameliorating adverse event peripheral neuropathies in a subject undergoing treatment with an anti- CD30 antibody-drug conjugate and optionally also receiving concomitant chemotherapies.SOLUTION: 1. Provided is a method of treating a subject who has exhibited peripheral neuropathy of Grade 2 or greater after initiating treatment with an anti- 2mg antibody-drug conjugate therapy at a dose of CD30 / kg or greater, comprising administering the anti- 9mg antibody-drug conjugate therapy at a dose of 0. CD30 / kg.SELECTED DRAWING: None

The present application relates to the medical physics technical field, disclose a kind of radiotherapy dose prediction method, device, equipment and medium.The method comprises: obtaining the medical image of the radiotherapy region of patient, including the multiple two-dimensional slice images of radiotherapy region, planned target volume and organ at risk in radiotherapy region are region of interest;Each two-dimensional slice image and its adjacent two-dimensional slice image are input into conditional diffusion generation network, with the anatomical information of its region of interest as control condition, guide the process of gradually denoising of the noise map generated by diffusion model to the random dose distribution map of radiotherapy region, generate initial dose distribution map;Two-dimensional slice image is input into dose calibration network, and the dose of its region of interest is predicted, to calibrate the dose of region of interest in initial dose distribution map, generate target dose distribution map;The three-dimensional dose distribution of patient radiotherapy is determined in combination with the target dose distribution map of all two-dimensional slice images.

The invention discloses a damage monitoring imaging method and system for high-intensity focused ultrasound, and belongs to the technical field of medical monitoring. The method comprises the following steps: before treatment, transmitting amplitude-modulated sub-treatment dose ultrasonic waves to a target tissue and collecting signals, and calculating and accumulating to obtain a pre-treatment accumulated displacement diagram; after the HIFU ablation treatment is carried out, the same parameters are collected again and calculated to obtain a post-treatment accumulated displacement diagram; and carrying out difference and normalization processing on the front and back accumulated displacement diagrams, and finally generating a color coded damage monitoring image. Through accumulation and difference characteristic data processing, the tissue displacement response difference caused by damage is remarkably amplified, the problem that a traditional method is insufficient in low-power excitation and damage early-stage monitoring sensitivity is solved, early-stage, accurate and visual monitoring of a damage area in HIFU treatment is achieved, and the method is suitable for popularization and application. And an effective tool is provided for real-time regulation and control of the therapeutic dose.

The invention relates to the technical field of medical physics, and discloses a radiotherapy dose prediction method and device, equipment and a medium. The method comprises the steps that a medical image of a radiotherapy area of a patient is acquired, the medical image comprises a plurality of two-dimensional slice images of the radiotherapy area, and a planned target area and an organ at risk in the radiotherapy area are areas of interest; inputting each two-dimensional slice image and the two-dimensional slice image adjacent to the two-dimensional slice image into a conditional diffusion generation network, and by taking anatomical information of a region of interest of the conditional diffusion generation network as a control condition, guiding a process of gradually denoising a noise graph generated by adding noise to a random dose distribution graph of a radiotherapy region by a diffusion model to generate an initial dose distribution graph; inputting the two-dimensional slice image into a dose calibration network, predicting the dose of the region of interest of the two-dimensional slice image, calibrating the dose of the region of interest in the initial dose distribution diagram, and generating a target dose distribution diagram; and determining the three-dimensional dose distribution of the radiotherapy of the patient by combining the target dose distribution diagrams of all the two-dimensional slice images.

Disclosed are methods for dosing a drug for treating a medical condition in a subject in need thereof, comprising performing a first administering of the drug to the subject at various dose levels to provide a pharmacokinetic (PK) profile of the drug; obtaining parameters of the PK profile, wherein the parameters comprise Michaelis constant (KM), maximum velocity (VM), nonspecific first-order clearance (Cl), and maximal concentration (Cmax); determining transitional concentration (Ctrans) based on the parameters, wherein the PK profile of the drug exhibits a rapid transition at Ctrans; formulating a therapeutic dose of the drug based on Ctrans to reach a desired clinical endpoint at a pre-determined time point; and performing a second administering of the drug to the subject at the therapeutic dose for treating the medical condition.

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for purifying bacteriophage. Provided herein is are practicable methods, or protocols, that are “Good Laboratory Manufacturing Practice” (GLMP), for phage isolation, selection, liter-scaled cultivation, and purification. In alternative embodiments, GLMP protocols as provided herein employ membrane filtration processes to yield at least about 300 treatment doses at about 109 plaque-forming units with endotoxin levels within human therapeutic regulatory limits. In alternative embodiments, provided are formulations or pharmaceutical preparations of bacteriophage comprising 109 PFU, 1010 PFU, 1011 PFU, or 1012 PFU or more per unit dose and endotoxin levels below about 5.5 EU·mL−1, or below about 5.0 EU·mL−1.

The invention relates to the technical field of biological medicine, in particular to application of TRIM21 serving as a biomarker in screening or preparing a preparation for reducing ciprofloxacin exposure related abortion risk. The problems that in the prior art, key action links and molecular mechanisms of pregnancy loss caused by exposure of environment or non-therapeutic dose ciprofloxacin are not clear, and objective detection markers capable of prompting risk states in the early stage of pregnancy and relatively standard and repeatable detection methods are lacked are solved. The invention discloses an application of TRIM21 as a biomarker in screening or preparing a preparation for reducing miscarriage risk related to ciprofloxacin exposure, the pregnancy risk caused by ciprofloxacin exposure can be recognized in an early stage by detecting the expression level of TRIM21, and a candidate preparation with a protective effect is further screened. The invention provides a new thought and target for developing a novel medicine for preventing abortion.

Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.

The invention provides a radiotherapy dose real-time monitoring system, which comprises a data interface module for acquiring multi-source data related to radiotherapy in real time, the multi-source data comprises plan data imported from a treatment plan system, and the plan data comprises three-dimensional plan dose distribution and plan anatomical structure data; according to the invention, the real-time dynamic monitoring of the radiation treatment dose is realized, the limitation that only pre-verification before treatment or offline analysis after treatment can be carried out in the traditional technology is broken through, the treatment plan data, the machine operation parameters and the real-time anatomical image of the patient are integrated, and the real-time monitoring of the radiation treatment dose is realized. A multi-source data fusion processing mechanism is innovatively constructed, the comprehensive influence of machine execution deviation and anatomical change of a patient on the dose is quantified in real time, actual dose distribution in a body is dynamically reconstructed, dose delivery is changed from an invisible black box state to a real-time traceable visual process, and accurate monitoring of the radiotherapy dose in treatment is truly realized.

The invention belongs to the field of medicines, and discloses application of macastine B in preparation of anti-inflammatory, repair-promoting and relapse and metastasis-resisting medicines after liver cancer operation. The invention discloses an application of macastine B in preparation of a medicine for recovering a liver cancer patient after partial liver resection. The macaxantin B can promote liver function recovery, reduce the level of inflammatory factors of liver tissues and serum species, and reduce the tumor recurrence rate and the tumor visceral metastasis rate after tumor excision after an orthotopic liver cancer surgical operation, and compared with simultaneous administration of a liver protection drug and an anti-tumor drug, the macaxantin B has the advantages that the liver metabolism burden is reduced, and the curative effect is improved. And a novel drug treatment choice is provided for disease management of a liver cancer patient in a perioperative period. The invention discloses a medicine for promoting postoperative recovery of an orthotopic liver cancer surgical operation. The medicine comprises an effective therapeutic dose of macastine B and pharmaceutically acceptable auxiliary materials.

The application discloses an image segmentation method for evaluating a neutron treatment dose in hepatocellular carcinoma, and relates to the technical field of neutron treatment. The application trains a 3D U-Net GAN network model through a medical image dataset, alternately trains a generator model and a discriminator model in the 3D U-Net GAN network model by using real images and false images randomly generated by the generator model, so that the generator model after training can generate a segmentation result which is more accurate and detailed for the medical image, the discriminator model after training can more accurately evaluate the authenticity of the output of the generator model, and the network after training can accurately reflect the anatomical structure of the patient itself when segmenting the medical image, 10 The distribution of B in the body and the radionuclide kinetics are favorable for fully displaying information in the medical image accurately and conveniently.